While there are no guarantees in life, we can safely say that...

While there are no guarantees in life, we can safely say that each of Imugene's products show extremely strong promise.

Azer-cel with it's groundbreaking Allogeneic method of use if successfully curing patients after 4-5 lines of prior treatment, readily availailable and cheaper to administer, and with an improved safety profile to the current Autopogous CAR-T products.

OnCARlytics offering the only product currently shuttling up a CD-19 protein with an Oncolytic virus that will help cutting edge CD-19 therapies identify solid tumours, which as we know are 90% of the cancer market.
This product if successful in performing as it did in the lab will therefore be naturally combined with Azer-cel as many have previously stated.

Vaccinia the strongest form of Yuman Fong's cancer killing virus with Symporter gene hNIS is still dose escalating and being trialed with Cholangiocarcinoma following the outstanding result with one patient going over 2 years cancer free.
CF33 may also be used with other treatment to help not only kill the cancer but also to boost the patients immune system.

It is so hard to comprehend how the share-price could reach 63c with not one of these groundbreaking therapies, and yet with them in ph1 human trials the shareprice languishes at under 4c.

I refuse to believe thàt these facts can be rationalised at the same time without some sort of devastating collapse of confidence in the company and the peòple running it.
Or some failure in current trials which prevents the ongoing development of them, which neither of the above circumstances has eventuated.

So, in my mind anyway there must be other reasons behind this unfathomable fact, others may wish to find answers to this.

DYOR opinion only